$pubTitle$
Drug giants AstraZeneca and Pfizer are working on a new clinical trial design, to be launched in Britain in July or August of this year, to include multiple drugs for evaluation in a single trial. This is expected to be both time and cost saving and could significantly hasten drug development.
Doctors should consider expensive new hepatitis C drugs for patients with advanced liver disease, including those awaiting transplants, but ask most others to wait for drugs in development, the Department of Veterans Affairs said Wednesday.
President Obama’s health law has led to an even greater increase in health coverage than previously estimated, according to new Gallup survey data, which suggest that about 12 million previously uninsured Americans have gained coverage since last fall.
The world’s largest organization of cancer doctors plans to rate the cost effectiveness of expensive oncology drugs, and will urge physicians to use the ratings to discuss the costs with their patients.
Multispecialty medical practices with non-physician providers typically perform better financially than those without physician assistants and nurse practitioners.
A US Department of Health and Human Services (HHS) analysis determined that a new payment formula, which would reduce Medicaid reimbursement rates for generic prescription drugs, could save Medicaid up to $1.2 billion per year. So why are pharmacists and drug manufacturers pushing back?
Pharmacists and drug manufacturers are pushing the CMS for a one-year transition period before states attempt to implement a new formula mandated under the Patient Protection and Affordable Care Act that will significantly trim Medicaid reimbursement rates for generic drugs.

Issue List